This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO 2022
ASCO 2022
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2022 Kidney Cancer
Viewing 1-19 of 19 articles
ASCO 2022: Sequencing Challenges in Renal Cell Carcinoma: What to Do Next? - Discussion
ASCO 2022: Moving Beyond TKI and Immuno-oncology in Renal Cell Carcinoma - Discussion
ASCO 2022: Pembrolizumab + Axitinib Versus Sunitinib As First-Line Therapy for Advanced Clear Cell RCC: Analysis of Progression After First Subsequent Therapy in KEYNOTE-426
ASCO 2022: Sequential Immunotherapy in Rare Variant Renal Cell Carcinoma Final Report of UNISoN (ANZUP 1602): Nivolumab Then Ipilimumab + Nivolumab in Advanced Nonclear Cell Renal Cell Carcinoma
ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations
ASCO 2022: Outcomes With Novel Combinations in Non-Clear Cell RCC: ORACLE Study
ASCO 2022: The Prognostic Role of Nephrectomy in Patients With mRCC Treated With Immunotherapy According to the Novel Prognostic Meet-URO Score: Sub-Analysis of the Meet-URO 15 Study
ASCO 2022: Prognostic Value of the Lung Immune Prognostic Index in Patients With Untreated Advanced RCC Receiving Nivolumab + Ipilimumab or Sunitinib in the CheckMate 214 Trial
ASCO 2022: Prognostic Factors for Patients With Advanced RCC in the Era of First-Line Treatment With Immune Checkpoint Inhibitors
ASCO 2022: Distinct Outcomes in Hispanic/Latinx and Non-Hispanic/Latinx Patients With Metastatic RCC Treated With First-Line Ipilimumab + Nivolumab
ASCO 2022: Healthcare Resource Utilization and Costs for Patients With mRCC Receiving First-Line Pembrolizumab + Axitinib or Ipilimumab + Nivolumab
ASCO 2022: Racial Differences in Treatment Patterns and Outcomes of First-Line Therapies for Advanced RCC in the Real-World Setting
ASCO 2022: LITESPARK-004 (MK-6482-004) Phase 2 Study of Belzutifan, an Oral HIF-2α Inhibitor, for Von Hippel-Lindau Disease: Update With More Than Two Years of Follow-Up Data
ASCO 2022: PSMA PET-CT for Advanced Renal Cell Carcinoma
ASCO 2022: Are We Improving Outcomes Comprehensively in Renal Cell Carcinoma? - Discussion
ASCO 2022: The Relationship Between Health-Related Quality of Life (HRQoL) and Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma (aRCC) in CheckMate (CM) 214
ASCO 2022: CALYPSO: A Three-Arm Randomized Phase II Study of Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer
ASCO 2022: Association Between Depth of Response (DepOR) and Clinical Outcomes: Exploratory Analysis in Patients with Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 9ER
ASCO 2022: EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy—A Phase III Study (SWOG S0931)
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free